

Document ID No.: 700152000

Revised Form PTO-1595 (Rev. 6-93)		RECORDATION FORM COVER SHEET		U.S. Department of Commerce Patent and Trademark Office	
PATENTS ONLY				Document ID No.: 700152000	
To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.					
1. Name of conveying party(ies): Ceptyr, Inc. 3830 Monte Villa Parkway, Suite 200 Bothell, Washington 98021 Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		2. Name and address of receiving party(ies): Name: <u>Amgen Inc.</u> Internal Address: _____ Street Address: <u>One Amgen Center Drive</u> City: <u>Thousand Oaks</u> State: <u>CA</u> Zip: <u>91320-1799</u> Additional name(s) & address(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			
3. Nature of conveyance: <input type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input checked="" type="checkbox"/> Other <u>Security Interest Agreement</u> Execution Date: <u>December 21, 2004</u>					
4. Application number(s) or patent number(s): If this document is being filed together with a new application, the execution date of the application is: _____ A. Patent Application No.(s) <u>10/390,501</u> <u>10/723,606</u> B. Patent No.(s) <u>6,114,140</u> <u>6,552,169</u> Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No					
5. Name and address of party to whom correspondence concerning document should be mailed: Name: <u>U.S. Patent Operations/BBT</u> Internal Address: <u>Dept. 4300, M/S 27-4-A</u> <u>AMGEN INC.</u> Street Address: <u>One Amgen Center Drive</u> City: <u>Thousand Oaks</u> State: <u>CA</u> Zip: <u>91320-1799</u>		6. Total number of applications and patents involved: <u>4</u> 7. Total fee (37 CFR 3.41).....\$ <u>160.00</u> <input type="checkbox"/> Enclosed <input checked="" type="checkbox"/> Authorized to be charged to deposit account. 8. Deposit account number: <u>01-0519</u> <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519			
DO NOT USE THIS SPACE					
9. Statement and signature. <i>To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.</i> <u>Sherry St. Andrew</u> <u>Sherry St. Andrew</u> <u>February 15, 2004</u> Name of Person Signing Signature Date Total number of pages including cover sheet, attachments, and document: <u>4</u>					

CH \$160.00 010519 10390501

700154377

PATENT
REEL: 015711 FRAME: 0639

EXHIBIT A: Assignment**Short Form Assignment of CSH Agreement for Recording Purposes**

This short form Assignment Agreement (the "Agreement") is made effective and entered into as of December 21, 2004 (the "Effective Date"), by and between CEPTYR, Inc., a Delaware corporation, having its principal place of business at 3830 Monte Villa Parkway, Suite 200, Bothell, Washington 98021 ("Ceptyr") and Amgen Inc., a Delaware corporation, having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799 ("Amgen"). "Party" refers to either Amgen or Ceptyr, and "Parties" refers to Amgen and Ceptyr collectively.

For Ten U.S. Dollars (U.S. \$10) and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Ceptyr hereby assigns to Amgen all rights, title and interest in and to that certain License Agreement dated June 14, 1996 and relating to DEP-1, PTPH-1 and PP, each as defined in such License Agreement (and the exclusive license to the patents set forth on Schedule 1 attached hereto), by and between Cold Spring Harbor Laboratory and CEPTYR, Inc. (the successor-in-interest to all of the rights and obligations of Charybdis Corporation as the result of the sale, transfer or merger of the business of Charybdis Corporation) (the "CSH Agreement"), and Amgen hereby accepts and assumes the CSH Agreement, including all of the rights and obligations of Ceptyr thereunder.

IN WITNESS WHEREOF, the Parties have executed this Agreement in duplicate originals by their duly authorized representatives as of the Effective Date.

AMGEN INC.

By: 

Name: Roger M. Perlmutter, M.D., Ph.D.

Title: Executive VP, Research & Development

CEPTYR, INC.

By: 

Name: Paul G. Adams

Title: Pres & CEO



Schedule 1
Exclusively Licensed Patents

Seed IP Ref:	Title:	Country:	Status:	Application No.:	Filing Date:	Patent No.:	Issue Date:
200125.402	DNA ENCODING DENSITY ENHANCED PROTEIN TYROSINE PHOSPHATASES CELL-DENSITY ENHANCED PROTEIN TYROSINE		Granted	08/854585	12-May-1997	6114140	05-Sep-2000
200125.40201EP	PHOSPHATASES DENSITY ENHANCED PROTEIN TYROSINE	European Patent	Convention Pending	3008169.9	03-May-1995		
200125.402C1	PHOSPHATASES DENSITY- ENHANCED PROTEIN TYROSINE	United States of America	Granted	09/447533	23-Nov-1999	6552169	22-Apr-2003
200125.402C2	PHOSPHATASE DENSITY ENHANCED PROTEIN TYROSINE	United States of America	Published	10/390501	13-Mar-2003		
200125.402CA	PHOSPHATASES DENSITY ENHANCED PROTEIN TYROSINE	Canada	Pending	2166479	03-May-1995		
200125.402CH	PHOSPHATASES DENSITY ENHANCED PROTEIN TYROSINE	Switzerland	Granted	95918943.2	03-May-1995	708831	09-Apr-2003
200125.402DE	PHOSPHATASES DENSITY ENHANCED PROTEIN TYROSINE	Germany	Granted	95918943.2	03-May-1995	708831	09-Apr-2003
200125.402DK	PHOSPHATASES DENSITY ENHANCED PROTEIN TYROSINE	Denmark	Granted	95918943.2	03-May-1995	708831	09-Apr-2003
200125.402EP	PHOSPHATASES DENSITY ENHANCED PROTEIN TYROSINE	European Patent	Converted	95918943.2	03-May-1995	708831	09-Apr-2003
200125.402FR	TYROSINE	France	Granted	95918943.2	03-May-1995	708831	09-Apr-2003

RightFax

2/10/05 9:33

PAGE 006/007

Fax Server

Seed IP Ref:	Title:	Country:	Status:	Application No.:	Filing Date:	Patent No.:	Issue Date:
200125.402GB	PHOSPHATASES DENSITY ENHANCED PROTEIN TYROSINE PHOSPHATASES	United Kingdom	Granted	95918943.2	03-May-1995	708831	09-Apr-2003
200125.402IE	PHOSPHATASES DENSITY ENHANCED PROTEIN TYROSINE PHOSPHATASES	Ireland	Granted	95918943.2	03-May-1995	708831	09-Apr-2003
200125.402IT	PHOSPHATASES DENSITY ENHANCED PROTEIN TYROSINE PHOSPHATASES	Italy	Granted	95918943.2	03-May-1995	708831	09-Apr-2003
200125.402JP	PHOSPHATASES DENSITY ENHANCED PROTEIN TYROSINE PHOSPHATASES	Japan	Pending	7-528507	03-May-1995		
200125.402NL	PHOSPHATASES DENSITY ENHANCED PROTEIN TYROSINE PHOSPHATASES	Netherlands	Granted	95918943.2	03-May-1995	708831	09-Apr-2003
200125.402PC	PHOSPHATASES DENSITY ENHANCED PROTEIN TYROSINE PHOSPHATASES	Patent Cooperation Treaty	Converted	US95/05512	03-May-1995		
200125.402SE	PHOSPHATASES DENSITY ENHANCED PROTEIN TYROSINE PHOSPHATASES	Sweden	Granted	95918943.2	03-May-1995	708831	09-Apr-2003
200125.447	DEP-1 RECEPTOR TYROSINE PHOSPHATASE INTERACTING PROTEINS AND RELATED METHODS	United States of America	Published	2004/0161821A1	26-Nov-2003		
200125.447PC	DEP-1 RECEPTOR TYROSINE PHOSPHATASE INTERACTING PROTEINS AND RELATED METHODS	Patent Cooperation Treaty	Published	WO 2004/048549 A2	26-Nov-2003		